RCUSArcus Biosciences, Inc.
$24.39+97% 1Y
$24.39
$12.3752 weeks$31.57
Is the price fair?
What RCUS's price assumes
Arcus Biosciences, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 32.5× revenue.
32.5
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 8.20
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 27.4
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 8.20
- EV / EBIToperating margin −415%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 27.4
- Market capitalisation
- $3.80B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks